Knowledge Graph · Biomarker

Body Mass Index

A value derived from mass and height, used to categorize weight status.

Authoritative sources

Evidence base

Randomized Controlled Trial · 2025
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
The New England journal of medicine · Packer M, Zile MR, Kramer CM, Baum SJ, et al.
Phase III Clinical Trial · 2025
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
The New England journal of medicine · Nicholls SJ, Pavo I, Bhatt DL, Buse JB, et al.
Randomized Controlled Trial · 2025
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
The New England journal of medicine · Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, et al.
Randomized Controlled Trial · 2024
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
JAMA · Aronne LJ, Sattar N, Horn DB, Bays HE, et al.
Randomized Controlled Trial · 2024
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
The New England journal of medicine · Malhotra A, Grunstein RR, Fietze I, Weaver TE, et al.
Randomized Controlled Trial · 2024
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
The New England journal of medicine · Bliddal H, Bays H, Czernichow S, Uddén Hemmingsson J, et al.
Randomized Controlled Trial · 2024
Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial
JAMA · Zhao L, Cheng Z, Lu Y, Liu M, et al.
Randomized Controlled Trial · 2023
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Lancet (London, England) · Garvey WT, Frias JP, Jastreboff AM, le Roux CW, et al.
Randomized Controlled Trial · 2022
Tirzepatide Once Weekly for the Treatment of Obesity
The New England journal of medicine · Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, et al.
Randomized Controlled Trial · 2021
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial
JAMA · Rubino D, Abrahamsson N, Davies M, Hesse D, et al.
Randomized Controlled Trial · 2021
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Lancet (London, England) · Davies M, Færch L, Jeppesen OK, Pakseresht A, et al.

Where Body Mass Index appears on Kindr Health

No content is currently linked to this entity.

This page is part of Kindr Health's public Knowledge Graph. Content is for educational purposes only and is not medical advice.